Categories
All News News

Human Factors Engineering And Usability Testing Services Market for medical devices is projected to reach USD 1 Billion by 2030, claims Roots Analysis

Human factors engineering and usability testing have now become an essential part of product design across almost all industries, offering developers the chance to optimize proprietary products in alignment to the preferences of consumers

Roots Analysis has announced the addition of “Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020-2030” report to its list of offerings.

Given the growing regulatory stringency, there are a number of medical devices recalls reported each year. Moreover, as such solutions are gradually becoming increasingly complex, it is imperative to identify potential risks / hazards, in order to guarantee safety to end users post product launch. This has led many device developers to resort to human factors engineering and usability testing. However, the aforementioned processes require specialized resources and expertise. Therefore, outsourcing this aspect of product design and development, has become common among industry stakeholders.

Key Market Insights

Around 105 companies / organizations claim to be engaged in offering human factors engineering and usability testing services for medical devices

It is worth noting that this market is currently dominated by the presence of small players (2 to 50 employees), which represent more than 67% of the players. Further, more than 50% of the firms engaged in providing human factors engineering and usability testing services were established post 2000.

Majority (57%) of the players engaged in this domain offer services for hospital / laboratory equipment and instruments

Various companies (53%) engaged in this domain claim to offer human factors engineering and usability testing services for diagnostic devices, followed by those providing support for drug delivery devices (44%), home use medical devices (36%), clinical use devices (26%) and therapeutic devices (25%).

More than 90% companies provide design and development services for medical devices

Currently, over 80 players provide services for prototype design and development, while almost 70 firms offer services for interface development. In addition, 83% service providers offer verification and validation services; of these 65% players provide services for both formative testing and summative testing.

Implementation of human factors engineering and usability testing, at initial stages of device design and development, has been demonstrated to enable significant cost savings 

We believe that, by 2030, an increase in adoption (up to 41%) of human factors engineering and usability testing services for medical devices is likely to be observed, resulting in savings worth USD 1.4 billion.  Incorporation of such novel approaches is also anticipated to help developers in achieving high return on investments, in the range between 5:1 to 9:1.

By 2030, the market is anticipated to be worth close to USD 1 billion, growing at an annualized rate of 14.2%. 

Based on the revenues generated from different services for usability testing, currently, the maximum share is expected to be generated through evaluative testing methodologies (61%), followed by generative testing methodologies (39%).

The USD 1 Billion (by 2030) financial opportunity within the human factors engineering and usability testing service providers market has been analysed across the following segments:

Type of tools used

  • Generative tools
  • Evaluative tools

Steps involved

  • Contextual analysis
  • Task analysis
  • Design analysis
  • Formative studies
  • Use risk analysis
  • Known use error analysis
  • Summative studies
  • Regulatory document preparation

Device class

  • Class I
  • Class II
  • Class III

Key geographical regions

  • North America
  • Europe
  • Asia Pacific

The research covers profiles of key players (mentioned below) that offer human factors engineering and usability testing services for medical devices; each profile features an overview of the company, details related to its human factors engineering and usability testing portfolio, recent developments and an informed future outlook.

  • Agilis
  • Human Factors Consulting Services
  • Human Factors MD
  • User wise
  • Ximedica
  • Austrian Center for Medical Innovation and Technology (ACIMT)
  • Auxergo
  • THAY Medical
  • Ergotech
  • Jonathan Bar-Or Industrial Design

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/human-factors-engineering-and-usability-testing-services.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

High Energy / Hazardous Chemistry-based API manufacturing services market is estimated to be worth USD 29 billion in 2030, predicts Roots Analysis

Although hazardous reaction chemistries are not used during early drug development stages owing to the associated risks, they offer a wide range of benefits over traditional approaches, especially from the perspective of large-scale manufacturing

Roots Analysis is pleased to announce the publication of its recent study, titled, “High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030.”

The report features an extensive study on the current landscape and the likely future potential of the companies offering services for API manufacturing based on high energy chemistry (HEC) / hazardous chemistry. The study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of service providers offering contract and custom services for HEC / hazardous chemistry-based API manufacturing.
  • A detailed list of around 150 manufacturing facilities equipped to handle API manufacturing under high temperature, low temperature, high pressure and low pressure conditions.
  • A competitiveness 3-D bubble analysis of HEC / hazardous chemistry-based contract and custom manufacturers
  • Elaborate profiles of the key players that offer a diverse range of capabilities for API manufacturing based on HEC / hazardous chemistry.
  • A qualitative case study providing insights on the general reaction portfolio related to small molecule synthesis processes.
  • A detailed case study presenting a list of contract research organizations (CROs) and custom synthesis service providers engaged in this domain.
  • A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Reaction Conditions

  • High Temperature
  • Low Temperature
  • High Pressure
  • Low Pressure

Key Geographical Region

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

The report features inputs from the following eminent industry stakeholders, according to whom, as more companies become aware of the benefits of exploiting novel synthetic routes, via hazardous reaction chemistries, for drug development, the demand for HEC-based manufacturing services may be anticipated to increase in the coming years.

  • Eric Fang, Chief Scientific Officer, Snapdragon Chemistry
  • Anonymous, Novasep
  • Edward Price, President / Chief Executive Director, PCI Synthesis

Key companies covered in the report

  • AGC Chemicals
  • Beijing Mediking Biopharm
  • Cambrex
  • CordenPharma
  • Evonik Industries
  • Hovione
  • Patheon
  • PCI Synthesis
  • Siegfried

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/high-energy-chemistry.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Endocannabinoid System Targeted Therapeutics Market is projected to be over USD 5 billion by 2030, growing at an annualized rate of 30%, claims Roots Analysis

So far, more than 100 different types of cannabinoids have been identified and there is a growing body of evidence supporting the benefits of this class of compounds in offering symptomatic relief for a wide variety of chronic health conditions

Roots Analysis has announced the addition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.

Key Market Insights

Over 175 drugs targeting the endocannabinoid system are currently under development

Most cannabinoid-based drug candidates are being developed to target the CB1 and CB2 receptors. Nearly 45% of such drugs are presently being investigated in clinical trials, while 50% are in the preclinical / discovery phase. Majority of these therapies (60%) are designed for oral administration.

More than 60 companies claim to develop endocannabinoid system targeted therapeutics

Post 2010, there has been a significant rise in the number of companies working in this domain; such companies represent 63% of the total number of players. Majority of the firms engaged in this domain (74%) are based in North America, followed by those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America (2%).

Partnership activity has grown at an annualized rate of 35%, between 2017 and 2019 

The maximum number of partnerships were observed in 2019 within this segment of the pharmaceutical industry. Majority of these agreements were reported to have been inked for research purposes (20%). In addition, more than 35 merger / acquisition deal were signed between 2016 and 2020; service / facility expansion emerged as the most prominent key value drivers for such agreements.

Close to 600 grants were awarded for supporting research on endocannabinoid system targeted therapeutics, since 2016

Almost 45% of the total amount awarded in the form of grants, was under the R01 (in support of health-related research and development based on the mission of the NIH) mechanism. Further, grants (394) worth USD 147 million were awarded to research projects related to endocannabinoid system.

At present, therapies intended for the treatment of neurological disorders represent the majority share of the overall endocannabinoid system targeted therapeutics market

Most of the therapies targeting neurological disorders are intended for the treatment of epilepsy. In addition to neurological disorders, therapies intended for autoimmune disorders, cancer and genetic disorders are likely to capture significant market opportunity in the foreseen future.

The over USD 5 billion (by 2030) financial opportunity within the Endocannabinoid System Targeted Therapeutics Market has been analyzed across the following segments:

Target Disease Indication

  • Cancer
  • Genetic Disorders
  • Neurological Indications
  • Others

Route of Administration

  • Oral
  • Inhalation

Key Geographies

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

The report features inputs from eminent industry stakeholders, according to whom, endocannabinoid system targeted therapeutics are considered as a promising alternative for the treatment of a diverse array of symptoms associated with a myriad of human diseases. The report includes detailed transcripts of the discussions held with industry experts.

  • Oludare Odumosu (Chief Executive Officer, Zelira Therapeutics)
  • Andrea Small-Howard (Chief Scientific Officer, GB Sciences)
  • Steeve Néron (Chief Operating Officer, Tetra Bio-Pharma)
  • Stephen Dahmer (Chief Medical Officer, Vireo Health)
  • Anthony Kievid (Director of Business Development, Echo Pharmaceuticals)
  • JANAKAN KRISHNARAJAH (Chief Operating Officer and Chief Medical Officer, iX Biopharma)

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), drug portfolio, recent developments and an informed future outlook.

  • GW Pharmaceuticals
  • Corbus Pharmaceuticals
  • Tilray
  • Tetra Bio-Pharma
  • Botanix Pharmaceuticals
  • Kalytera Therapeutics
  • Therapix Biosciences
  • Echo Pharmaceuticals
  • Avicanna
  • GB Sciences

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chau[email protected]

Categories
All News News

Contract Regulatory Affairs-Management Services Market for medical devices is estimated to be worth USD 820 million by 2030, growing at a CAGR of 6.9%, claims Roots Analysis

Over the years, outsourcing has become a popular trend with the medical device industry, allowing innovators to leverage the technical and regulatory expertise of contract service providers in order to expedite time to market

Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CROs for Regulatory Affairs Management Market, 2019-2030.”

The report features a detailed study on the current landscape of contract service providers focused on regulatory affairs management for medical devices. The study features an in-depth analysis, highlighting the capabilities of the various CROs engaged in this domain, across different regions of the globe. Amongst other elements, the report includes:

  • A detailed review of the current market landscape of the medical devices regulatory affairs outsourcing market, featuring a list of over 400 CROs engaged in this domain.
  • A detailed discussion on the need for regulatory review / oversight across different stages of the medical devices supply chain, with emphasis on the optimization of the supply chain using upcoming tools / technologies.
  • An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, Asia-Pacific and rest of the world.
  • Elaborate profiles of popular players that specialize in offering end-to-end regulatory services for medical devices across key geographies.
  • A benchmark analysis, highlighting the key focus areas of very small-sized, small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.
  • An elaborate discussion on the various outsourcing business models adopted for regulatory affairs management, along with an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a CRO partner.
  • An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers that are active in the domain, based on information gathered via secondary research (for top-ten medical device players) and primary research.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing regulatory affairs management services to medical device developers.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Medical Device Class

  • Class I
  • Class II
  • Class III

Therapeutic Area

  • Cardiovascular Disorders
  • CNS Disorders
  • Metabolic Disorders
  • Oncological Disorders
  • Ophthalmological Disease
  • Orthopedic Disorders
  • Pain Disorders
  • Respiratory Disorders
  • Others

Type of Regulatory Affairs Service

  • Pharmacies GAP-Analysis
  • Pharmacies Legal Representation
  • Pharmacies Notified Body Selection
  • Product Labelling-related Services
  • Product Registration and Clinical Trial Applications
  • Regulatory Document Submissions
  • Regulatory Writing and Publishing
  • Risk Management-related Services
  • Technical Dossier Set-up
  • Vigilance & Medical Device Report

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific and Rest of the World

Key companies covered in the report

  • CTI Clinical Trial and Consulting Services
  • CROMSOURCE
  • ICON
  • Intertek
  • Medpace
  • MIC Medical
  • North American Science Associates (NAMSA)
  • Parexel
  • PharmaLex
  • Premier Research
  • Société Générale de Surveillance (SGS)
  • Underwriters Laboratory (UL)

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/med-dev-regulatory/282.html      

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Contract Manufacturing Market for Pharmaceuticals in China is estimated to be worth USD 13 billion in 2030, predicts Roots Analysis

Owing to reasons, such as a booming economy and availability of skilled labor, outsourcing to Asian CMOs, primarily in China, is considered an attractive business model to pharmaceutical developers / sponsors, across the world.

Roots Analysis is pleased to announce the publication of its recent study, titled, “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030.”

The report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region. Amongst other elements, the report features:

  • A detailed assessment of the current market landscape of pharmaceutical contract manufacturers in China engaged in the development of active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs).
  • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
  • A brief discussion of various regulatory guidelines in China and various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
  • Detailed profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China.
  • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues).
  • An analysis of the partnerships and acquisitions that have been established in this domain, in the recent past.
  • A detailed capacity analysis based on the installed reactor capacities of the manufacturing facilities in China.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Key Geographical Regions

  • Eastern China
  • Southern China
  • Northern China

Type of Product

  • Active Pharmaceutical Ingredients (APIs)
  • Drug Products

Type of Drug Product

  • Solid
  • Liquid / Semi-Solid
  • Injectable
  • Others

Scale of Operation

  • Clinical
  • Commercial

Company Size

  • Small
  • Mid-Sized
  • Large / Very Large

Key players covered in the report

  • 2Y-Chem
  • Aurisco Pharmaceutical
  • ChemPartner
  • Dorrapharma
  • Hubei Biocause Pharmaceutical
  • Infoark
  • Ningbo Menovo Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • STA Pharmaceutical
  • Zhejiang Huahai Pharmaceutical

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Collaborative Robots (Cobots) Market is projected to be worth USD 18 billion by 2030, growing at a CAGR of 34.4%, claims Roots Analysis

Given their flexibility and price to functionality ratio, cobots represent an ideal entry-level, automation model for both small and established companies, which do not intend to make very heavy large investments in automation

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Collaborative Robots (Cobots) Market, 2020-2030.”

The report features an extensive study of the potential applications, current landscape and the likely adoption of cobots across various industrial applications, over the next decade. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

  • An overview of the current market landscape of cobots and details of the cobot manufacturers.
  • An in-depth analysis of the contemporary market trends presented using four schematic representations.
  • Elaborate profiles of companies that are engaged in the development of cobots.
  • An insightful three-dimensional bubble chart representation, highlighting the competitiveness analysis of cobot manufacturers.
  • A detailed brand positioning analysis of key industry players, highlighting the current perceptions regarding their proprietary products.
  • A detailed competitiveness analysis of cobots based on various relevant parameters.
  • A discussion on key technological innovations (tools / technologies), such as advanced grippers, artificial intelligence, machine learning, vision technology and voice interface, in the cobots industry.
  • An insightful discussion on the effects of COVID-19 outbreak on the automation industry.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Payload Capacity

  • Below 6 Kg
  • Between 6 and 10 Kg
  • Above 10 Kg

Industrial Operation

  • Small Part Assembly
  • Case Packing
  • Material Handling
  • Palletizing / Depalletizing
  • Picking and Placing
  • Welding
  • Other Operations

End-User (Industry)

  • Automotive Industry
  • Food Processing Industry
  • Electrical / Electronic Industry
  • Plastic and Rubber Industry
  • Life Sciences / Pharmaceutical Industry
  • Metal Industry
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

Transcripts of interviews held with the following senior level representatives of stakeholder companies

  • Mineko Ogata (Owner, ROBOMOV)
  • David Sands (Chief Executive Officer, ST Robotics)
  • Barry Philips (Chief Marketing Officer, Fetch Robotics)
  • Brian Carlisle (President, Precise Automation)
  • Nilabdhi Samantray (Associate Vice President, Head of Data Science and Artificial Intelligence, Sector Leader (Mines and Minerals), CSM Technologies)
  • John Kehoe (Managing Director, Tekpak Automation)
  • Andreas Czezatke (Global Project Leader, SMC Austria)
  • Nelija Miseikiene (Sales and Marketing Specialist, F&P Robotics)
  • Michael Murray (Sales Specialist, Productive Robotics)
  • Aadya Avinash (Assistant Marketing Manager, Universal Robots)

Key companies covered in the report

  • ABB
  • Comau
  • FANUC
  • Kinova
  • KUKA
  • Precise Automation
  • Robotics Systems Integration
  • Staubli
  • Universal Robots
  • Yaskawa Electric

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/collaborative-robots-market.html       

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Cell Therapies and Encapsulation Technologies Market is projected to be over USD 3.7 billion by 2030 | Roots Analysis

Given the increasing number of licensing deals and the expected approval of multiple mid-late stage candidates, the encapsulated cell therapies and encapsulation technologies market is anticipated to evolve at a rapid pace over the next decade, predicts Roots Analysis

Roots Analysis has done a detailed study on Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Key Market Insights

  • Presently, over 45 encapsulated cell therapies and encapsulation technologies are being evaluated across different phases of development by stakeholders across the world
  • Ongoing therapy development programs are evaluating different types of cells, encapsulated in a wide range of biocompatible materials, aiming to offer viable and effective treatment options for various diseases
  • In fact, majority of the product candidates are being developed for the treatment of metabolic disorders, primarily diabetes; big pharma are driving a significant proportion of research and development activity
  • Clinical research in this field is growing at a fast pace; encapsulated therapy products are evaluating a number of pre-marketing end points to validate safety / efficacy
  • Over the years, more than 3,000 patents have been granted / filed related to cell encapsulation technologies, demonstrating the heightened pace of research in this domain
  • Foreseeing a lucrative future, several private and public investors have made capital investments worth approximately USD 1 billion, across over 100 funding instances, since 2013
  • Growth in partnership activity reflects the rising interest of stakeholders in this domain; over 70% of deals have been inked related to therapies for metabolic disorders, involving both international and indigenous parties
  • An evaluation of more than 300+ stakeholders engaged in cell therapies domain reveals the presence of several likely strategic partners spread across different geographical regions
  • The short term opportunity in this market is likely to be driven by licensing activity and will depend on the untapped potential of novel cell encapsulation technologies in different application areas
  • As multiple mid-late stage encapsulated cell therapies get commercialized in near future across different regions, the long term opportunity is likely to be distributed across diverse indications and encapsulation materials
  • The enormous potential of encapsulated cell-based therapies / devices in the treatment of chronic disorders has captured the interest of several stakeholders in the industry

Table of Contents

  1. PREFACE
    • Scope of the Report
    • Research Methodology
    • Chapter Outlines
  2. EXECUTIVE SUMMARY
  3. INTRODUCTION
    • Context and Background
    • An Overview of Cell Therapies
      • Cell Therapy Manufacturing
      • Supply Chain
      • Key Challenges
    • An Introduction to Cell Encapsulation
      • Historical Overview
      • Cell Encapsulation Approaches
      • Encapsulation Materials
      • Advantages and Challenges
    • Potential Applications of Cell Encapsulation
      • Targeted Drug / Therapy Delivery
      • Immunoprotection
      • Storage and Transportation
    • Key Growth Drivers and Road-blocks
  4. CURRENT MARKET LANDSCAPE
    • Chapter Overview
    • Encapsulated Cell Therapies and Encapsulation Technologies: Developer Landscape
      • Distribution by Year of Establishment
      • Distribution by Geographical Location
      • Distribution by Size of Developers
      • Distribution by Type of Offering
    • Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline
      • Distribution by Target Therapeutic Area
      • Distribution by Phase of Development
      • Distribution by Type of Cells and Other Encapsulated Components
      • Distribution by Type of Encapsulation Material Used
      • Distribution by Route of Administration
      • Distribution by Application Areas
    • Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players
  5. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR METABOLIC DISORDERS: COMPANY PROFILES
    • Chapter Overview
    • Developers with Clinical Candidates
      • Beta-O2 Technologies
        • Company Overview
        • Financial Information
        • Product Description: ꞵAir Bio-artificial Pancreas
        • Recent Developments and Future Outlook
      • Diatranz Otsuka
        • Company Overview
        • Financial Information
        • Product Description: DIABECELL®
        • Recent Developments and Future Outlook
      • Sernova
        • Company Overview
        • Financial Information
        • Product Description: Cell Pouch System™
        • Recent Developments and Future Outlook
      • ViaCyte
        • Company Overview
        • Financial Information
        • Product Description: PEC-Direct™ and PEC-Encap™
        • Recent Developments and Future Outlook
      • Developers with Preclinical Candidates
        • ALTuCELL
        • Beta-Cell
        • Betalin Therapeutics
        • CellProtect Biotechnology
        • Defymed
        • Encellin
        • Kadimastem
        • PharmaCyte Biotech
        • Semma Therapeutics
        • Sigilon Therapeutics
        • Seraxis
        • SymbioCellTech
  1. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR NON-METABOLIC DISORDERS: COMPANY PROFILES
    • Chapter Overview
    • Developers with Clinical Candidates
      • Azellon Cell Therapeutics
        • Company Overview
        • Financial Information
        • Product Description: Cell Bandage
        • Recent Developments and Future Outlook
      • EryDel
        • Company Overview
        • Financial Information
        • Product Description: EryDex System
        • Recent Developments and Future Outlook
      • Erytech Pharma
        • Company Overview
        • Financial Information
        • Product Description: GRASPA®
        • Recent Developments and Future Outloo
      • Gloriana Therapeutics
        • Company Overview
        • Financial Information
        • Product Description: EC-NGF
        • Recent Developments and Future Outlook
      • Living Cell Technologies
        • Company Overview
        • Financial Information
        • Product Description: NTCELL®
        • Recent Developments and Future Outlook
      • MaxiVAX
        • Company Overview
        • Financial Information
        • Product Description: MVX-ONCO-1
        • Recent Developments and Future Outlook
      • Neurotech Pharmaceuticals
        • Company Overview
        • Financial Information
        • Product Description: NT-501
        • Recent Developments and Future Outlook
      • PharmaCyte Biotech
        • Company Overview
        • Financial Information
        • Product Description: Cell-in-a-Box®
        • Recent Developments and Future Outlook
      • Developers with Preclinical Candidates
        • Beta-O2 Technologies
        • Sernova
        • Sigilon Therapeutics
  1. PATENT ANALYSIS
    • Chapter Overview
    • Scope and Methodology
    • Encapsulated Cell Therapies and Encapsulation Technologies: Patent Analysis
      • Analysis by Publication Year
      • Analysis by Geographical Location
      • Analysis by CPC Classifications
      • Emerging Focus Areas
      • Leading Players: Analysis by Number of Patents
    • Encapsulated Cell Therapies and Encapsulation Technologies: Patent Benchmarking Analysis (Industry Players)
      • Analysis by Patent Characteristics
      • Analysis by Geographical Locatio
    • Encapsulated Cell Therapies and Encapsulation Technologies: Patent Valuation Analysis
    • Leading Patents: Analysis by Number of Citations
  2. CLINICAL TRIAL ANALYSIS
    • Chapter Overview
    • Scope and Methodology
    • Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials
      • Analysis by Trial Registration Year
      • Geographical Analysis by Number of Clinical Trials
      • Geographical Analysis by Enrolled Patient Population
      • Analysis by Phase of Development
      • Analysis by Study Design
      • Analysis by Type of Sponsor / Collaborator
      • Most Active Players: Analysis by Number of Registered Trials
      • Analysis by Trial Focus
      • Analysis by Therapeutic Area
      • Analysis by Clinical Endpoints
  1. RECENT PARTNERSHIPS
    • Chapter Overview
    • Partnership Models
    • Encapsulated Cell Therapies and Encapsulation Technologies: Recent Collaborations and Partnerships
      • Analysis by Year of Partnership
      • Analysis by Type of Partnership
      • Analysis by Therapeutic Area
      • Analysis by Type of Cells and Other Encapsulated Components
      • Most Active Players: Analysis by Number of Partnerships
      • Analysis by Regions
        • Most Active Players
        • Intercontinental and Intracontinental Agreements
      • FUNDING AND INVESTMENT ANALYSIS
        • Chapter Overview
        • Types of Funding
        • Encapsulated Cell Therapies and Encapsulation Technologies: Recent Funding Instances
          • Analysis by Number of Funding Instances
          • Analysis by Amount Invested
          • Analysis by Type of Funding
          • Analysis by Number of Funding Instances and Amount Invested across Different Indications
          • Analysis by Amount Invested across Different Type of Cells and Other Encapsulated Components
          • Most Active Players: Analysis by Amount Invested
          • Most Active Investors: Analysis by Number of Instances
          • Geographical Analysis of Amount Invested
        • Concluding Remarks
      • GRANT ANALYSIS
        • Chapter Overview
        • Scope and Methodology
        • Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants
          • Analysis by Project Start Year
          • Analysis by Focus Area
          • Analysis by Support Period
          • Analysis by Type of Grant
          • Analysis by Amount Awarded
          • Analysis by Study Section
          • Analysis by Therapeutic Area
          • Analysis by Type of Cells and Other Encapsulated Components
          • Analysis by Type of Encapsulation Material
          • Leading Funding Institutes: Analysis by Number of Grants
          • Leading Recipient Organizations: Analysis by Number of Grants

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi–mmr-and-tils-testing-2019–2030/253.html     

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Cancer Biomarkers Market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis

Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019–2030.”

The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:

  • A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
  • An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
  • An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).
  • Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).
  • A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.
  • A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.
  • A discussion on various steps involved in development operations of companion diagnostics
  • A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of test

  • Laboratory Developed Tests (LDTs)
  • Companion Diagnostic Tests (CDx)

Type of disease indication

  • Breast cancer
  • Blood cancer
  • Colon / Colorectal cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer

Type of cancer biomarker

  • TMB
  • MSI / MMR
  • TILs

Type of analytical technique

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Others

Key geographical regions

  • North America
  • Europe
  • Japan
  • China
  • Australia

Key companies covered in the report

  • Foundation Medicine
  • NeoGenomics Laboratories
  • Novogene
  • Q2 Solutions
  • Personal Genome Diagnostics
  • Dr Lal PathLabs
  • Shenzhen Yuce Biotechnology

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi–mmr-and-tils-testing-2019–2030/253.html     

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Blood-Brain Barrier (BBB) Penetrating Drugs Market is estimated to be worth USD 900 million in 2030, predicts Roots Analysis

Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries

Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters
  • A detailed assessment of the current market landscape of BBB penetrant drugs.
  • Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.
  • An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.
  • Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.
  • An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.
  • An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.
  • An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).
  • An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.
  • An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
  • An assessment of the most commonly targeted disorders affecting the CNS, shortlisted on the basis of number of BBB penetrant drugs in development.
  • A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.
  • A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.
  • An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of Payment Model Adopted

  • Upfront payments
  • Milestone payments

Type of Molecule

  • Small Molecules
  • Biologics

Target Disease Indication

  • Brain Metastases in Breast Cancer
  • Glioblastoma Multiforme
  • Hunter Syndrome
  • Hurler Syndrome

Leading Technology Platforms

  • G®-Technology
  • J-Brain Cargo® Technology
  • LRP-1 Technology
  • Trojan Horse Technology

Leading Drug Developers

  • 2-BBB
  • Angiochem
  • ArmaGen
  • JCR Pharmaceuticals

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific

Transcripts of interviews held with the following senior level representatives of stakeholder companies

  • Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
  • Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
  • Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
  • Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
  • Mathias Schmidt (Chief Executive Officer, ArmaGen)
  • Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
  • Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
  • Carole Desseaux (Head of Clinical Affairs, CarThera)
  • Jamal Temsamani (Head of Drug Development, Vect-Horus)
  • Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Categories
All News News

Biologics Fill / Finish Services Market for biologics is anticipated to be worth USD 4.2 billion by 2030, predicts Roots Analysis

A steadily growing demand for biologic fill / finish services has generated a range of new opportunities for contract service providers; stakeholders have invested heavily to ensure product integrity and safety

Roots Analysis is pleased to announce the publication of its recent study, titled, “Biologics Fill / Finish Services Market, 2019-2030.”

The report features an extensive study on the contract service providers offering drug product manufacturing services within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of companies that claim to specialize in fill / finish operations. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of Biologics Fill / finish services market for biopharmaceuticals.
  • A region-wise, company competitiveness analysis, highlighting prominent fill / finish service providers across various packaging types.
  • Elaborate profiles of key players across key geographies (North America, Europe and Asia-Pacific).
  • An analysis of the recent collaborations (signed since 2013) focused on the Biologics Fill / finish services for biologics.
  • A detailed analysis of the expansions undertaken (since 2013) by various service providers for augmenting their respective fill / finish service portfolios.
  • An estimate of the global Biologics Fill / finish capacity, by taking into consideration the capacities of various fill / finish service providers.
  • An informed estimate of the annual demand for fill / finish of biologics, taking into account the top 20 biologics.
  • An analysis to identify the key performance indicators for service providers active in the domain.
  • A case study to highlight the benefits of using robotic / automated equipment for aseptic fill / finish processes.
  • A case study to highlight the role of ready-to-use packaging containers in aseptic fill / finish operations.
  • A discussion on the potential growth areas and recent trends impacting the outsourcing potential for biopharmaceuticals.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Types of Primary Packaging Containers

  • Ampoules
  • Cartridges
  • Syringes
  • Vials

Types of Biologics

  • Peptides / proteins
  • Antibodies
  • Vaccines
  • Cell therapies
  • Gene therapies
  • Viral products
  • Oligonucleotides
  • Others

Company Size

  • Small-sized
  • Mid-sized
  • Large / very large

Scale of Operation

  • Preclinical
  • Clinical
  • Commercial

Key Therapeutic Areas

  • Cancer
  • Infectious diseases
  • Autoimmune diseases
  • Cardiovascular diseases
  • Other indications

Key Geographical Regions

  • North America (US, Canada)
  • Europe (UK, France, Germany, Italy, Spain and rest of the Europe)
  • Asia-Pacific (Japan, China, South Korea, India and Australia)

The report features inputs from a number of eminent industry stakeholders, according to whom, “Currently, majority of biologics are being filled in vials, however, the scenario is likely to change in the future due to the growing demand and preference for self-administration devices.” The report features detailed transcripts of discussions held with the following experts:

  • Ales Sima, Business Development Manager, oncomed manufacturing
  • Gregor Kawaletz, Chief Commercial Officer, IDT Biologika
  • Jos Vergeest, International Business Developer, HALIX
  • Purushottam Singnurkar, Research Director and Head of Formulation Development, Syngene International

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/biologics-fill–finish-services-market-2019-2030/256.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]